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Androgens play an important role in metabolic homeostasis and reproductive health in both men and
women. Androgen signalling is dependent on androgen receptor activation, mostly by testosterone and
5a-dihydrotestosterone. However, the intracellular or intracrine activation of C19 androgen precursors to
active androgens in peripheral target tissues of androgen action is of equal importance. Intracrine
androgen synthesis is often not reﬂected by circulating androgens but rather by androgen metabolites
and conjugates. In this review we provide an overview of human C19 steroid biosynthesis including the
production of 11-oxygenated androgens, their transport in circulation and uptake into peripheral tissues.
We conceptualise the mechanisms of intracrinology and review the intracrine pathways of activation and
inactivation in selected human tissues. The contribution of liver and kidney as organs driving androgen
inactivation and renal excretion are also highlighted. Finally, the importance of quantifying androgen
metabolites and conjugates to assess intracrine androgen production is discussed.
© 2018 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Contents
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Androgens (from the greek “andro” meaning male or man) are
traditionally considered male sex steroids responsible for the
maintenance of male characteristics via the activation of the
Androgen Receptor (AR), a ligand-induced nuclear receptor that
functions as transcription factor after activation. The primary
androgen found in men is testosterone (T, androst-4-ene-17b-ol-3-
one), which is produced by the Leydig cells of the testes, and
released into circulation. The androgen signal can be further
ampliﬁed in selected target tissues where T is reduced to 5a-
dihydrotestosterone (DHT, 5a-androstan-17b-ol-3-one), which is
considered themost potent natural androgen (Pretorius et al., 2016;
Rege et al., 2013; Storbeck et al., 2013; Wilson and French, 1976).
While the adrenal glands only produce low levels of the active
androgen T, they produce signiﬁcant levels of the inactive C19
androgen precursors dehydroepiandrosterone (DHEA, androst-5-
ene-3bol-17-one) and its sulfate ester DHEAS, androstenedione
(A4, androst-4-ene-3,17-dione) and 11b-hydroxyandrostenedione
(11OHA4), which in the majority are released into circulation (Rege
et al., 2013). After uptake into a peripheral tissue with the required
enzyme machinery, these androgen precursors are converted into
active androgens which elicit a physiological response. This distinct
mechanism of androgen precursor activation, action and inactiva-
tion in peripheral androgen-target cells was ﬁrst termed intra-
crinology by Labrie et al. (1988) and is linked to classical genomic
androgen signalling in both men and women. The importance of
intracrinology has beenwell documented by several authors during
the last 25 years after the initial description by Labrie (1991, 2015),
Labrie et al. (2001, 2017) and signiﬁcant progress has been made in
understanding the tissue-speciﬁcity of intracrinology and its dys-
regulation, which is associated with, for example, metabolic
dysfunction and hormone dependent cancers. In this review, we
give an overview of the journey of C19 steroids from their synthesis
to their secretion as summarised in Fig. 1. We provide an overview
of human C19 steroid biosynthesis, the transport of these steroids in
circulation and uptake into peripheral target tissues of androgen
action. We conceptualise the mechanisms of intracrinology and
review the intacrine pathways and effects in selected tissues. The
contribution of liver and kidney as organs driving androgeninactivation and excretion are also highlighted. For ease of refer-
ence the enzymes discussed in this review are summarised in
Table 1 along with the names of the corresponding genes and their
enzymatic activities.
2. De-novo androgen biosynthesis in the adrenal and gonads
2.1. Adrenal androgen biosynthesis
Adrenal androgen biosynthesis takes place in the zona reticularis
and proceeds via the classical D5 pathway (Miller and Auchus, 2011;
Turcu and Auchus, 2015) as depicted in Fig. 2. The speciﬁc co-
localisation of the cytochrome P450 17a-hydroxylase/17,20-lyase
(CYP17A1) and cytochrome b5 in the zona reticularis favours the
17,20-lyase activity of CYP17A1 and thus C19 steroid production.
Furthermore, the expression of HSD3B2 encoding 3b-hydroxyste-
roid dehydrogenase/D54-isomerase type 2 (HSD3B2) is relatively
low in the zona reticularis, thereby ensuring the activity of the D5
pathway and the production of DHEA.
DHEA is converted to DHEAS by DHEA sulfotransferase (sulfo-
transferase 2A1, SULT2A1) and as such DHEAS is the major C19
steroid secreted by the adrenal, circulating in low micromolar
concentrations. Importantly, all sulfotransferases (SULTs) require
30-phospho-adenosine-50-phosphosulfate (PAPS), the ubiquitous
sulfate donor, which in humans is produced by the two isoforms of
PAPS synthase from sulfate and ATP. Mutations of PAPS synthase
type 2 (PAPSS2) lead to impaired PAPS synthesis and thus impaired
sulfation, which results in enhanced conversion of DHEA to active
androgens. Clinically this results in androgen excess manifesting
with premature pubarche and a phenotype in women resembling
polycystic ovary syndrome (PCOS), also observed in heterozygous
carriers of major loss-of-function mutations (Noordam et al., 2009;
Oostdijk et al., 2015). In the adrenal, DHEA can further be converted
to A4 by HSD3B2 and A4 can be transformed to T by the low adrenal
levels of aldo-keto-reductase family 1C3 (AKR1C3, also known as
17b-hydroxysteroid dehydrogensae type 5, HSD17B5), which has
17b-hydroxysteroid dehydrogenase (17bHSD) activity (Nakamura
et al., 2009b; Rainey and Nakamura, 2008; Rege et al., 2013).
AKR1C3 can also catalyse the conversion of some DHEA to 5-diol
(androst-5-ene-3b,17b-diol), which can be sulfated by SULT2A1 or
Fig. 1. Schematic overview of C19 steroid biosynthesis, intracrine action, metabolism and urinary excretion. Yellow balls represent the androgen sulfate, blue balls the
glucuronide. After metabolic activation the androgen binds the androgen receptor (red) and the complex translocates into the nucleus (grey) to work as transcription factor. It
should be noted that while intracrine pathways play the major role for peripheral androgen action, active androgens such as T are produced by the testes and the adrenal, albeit only
low levels, and these do not require activation in target tissue. CYP, cytochrome P450; HSD, hydroxysteroid dehydrogenase; SHBG, sex hormone binding globulin; STS, steroid
sulfatase; SULT, sulfotransferase.
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also be esteriﬁed with fatty acids at the 3b- or 17b-hydroxyl posi-
tion (Belanger et al., 1990; Hochberg, 1998). Due to the ample levels
of cytochrome P450 steroid 11b-hydroxylase (CYP11B1), the adre-
nal gives rise to 11-oxygenated C19 steroids by converting A4 and T
to their 11b-hydroxyl derivatives, with 11OHA4 being the major
product due to the high abundance of A4. Both 11OHA4 and 11b-hydroxytestosterone (11OHT) may be converted to their 11-keto
counterparts by the low levels of 11b-hydroxysteroid dehydroge-
nase type 2 (HSD11B2) present in the adrenal, though peripheral
HSD11B2 may make a more signiﬁcant contribution (Pretorius
et al., 2017; Turcu et al., 2016). Adrenal vein sampling of healthy
women has shown that the adrenal secretes DHEAS (low micro-
molar range) »DHEA,11OHA4, A4 (mediumnanomolar ranges)> 5-
Table 1
Summary of enzymes involved in androgen biosynthesis and metabolism. Genes are named according to HUGO nomenclature (Povey et al., 2001; Shows et al., 1979)
(http://www.genenames.org/). In the case of multi-functional enzymes only the major activity towards C19 steroids are listed. It should be noted that while hydroxysteroid
dehydrogenase enzymes are, in principle, bi-directional enzymes, their directionality in vivo (reductive or oxidative) is regulated in part by cellular redox status.
Gene
name
Enzyme name and abbreviation Enzymatic activity towards C19 steroids
AKR1C1 aldo-keto reductase 1C1, AKR1C1 reductive 3aHSD (minor)
AKR1C2 aldo-keto reductase 1C2, AKR1C2 reductive 3aHSD
AKR1C3 aldo-keto reductase 1C3, AKR1C3 (also known as 17b-hydroxysteroid dehydrogenase type 5, HSD17B5) reductive 17bHSD
AKR1C4 aldo-keto reductase 1C4, AKR1C4 reductive 3aHSD
AKR1D1 aldo-keto-reductase 1D1, 5b-reductase, AKR1D1 5b-reductase
CYP11A1 cytochrome P450 cholesterol side-chain cleavage, CYP11A1 C20-C22 bond cleavage
CYP11B1 cytochrome P450 11b-hydroxylase, CYP11B1 11b-hydroxylase
CYP17A1 cytochrome P450 17a-hydroxylase/17,20-lyase, CYP17A1 17a-hydroxylation and C17-C20 bond
cleavage
CYP19A1 cytochrome P450 aromatase, CYP19A1 C10-C19 demethylation/A-ring
aromatisation
HSD3B1 3b-hydroxysteroid dehydrogenase type 1, HSD3B1 oxidative 3bHSD/D54-isomerase
HSD3B2 3b-hydroxysteroid dehydrogenase type 2, HSD3B2 oxidative 3bHSD/D54-isomerase
HSD11B1 11b-hydroxysteroid dehydrogenase type 1, HSD11B1 (predominantly) reductive 11bHSD
HSD11B2 11b-hydroxysteroid dehydrogenase type 2, HSD11B2 oxidative 11bHSD
HSD17B3 17b-hydroxysteroid dehydrogenase type 3, HSD17B3 reductive 17bHSD
HSD17B6 17b-hydroxysteroid dehydrogenase type 6, HSD17B6 (also known as retinol dehydrogenase, RoDH with RoDH used
for the gene)
oxidative 3a-HSD
PAPSS2 30-phosphoadenosine 50-phosphosulfate synthase 2, PAPSS2 30-phosphoadenosine 50-
phosphosulfate synthase
SRD5A1 steroid 5a-reductase type 1, SRD5A1 5a-reductase
SRD5A2 steroid 5a-reductase type 2, SRD5A2 5a-reductase
SRD5A3 steroid 5a-reductase type 3, SRD5A3 5a-reductase (minor)
STS steroid sulfatase, STS hydrolysis of steroid sulfates
SULT2A1 sulfotransferase 2A1, also DHEA sulfotransferase, SULT2A1 sulfotransferase
SULT2B1 sulfotransferase 2B1 isoforms a and b, SULT2B1a and SULT2B1b sulfotransferase
Fig. 2. Schematic overview of C19 steroid biosynthesis in the adrenal. De-novo androgen biosynthesis in the zona reticularis of the adrenal proceeds via the classical D5 pathway.
CYP11B1 activity leads to the formation of 11-oxygenated C19 steroids. Major pathways are indicated by bold arrows and arrows are labelled with the major isoform of the enzyme
responsible for the reaction. Active androgens are shown in black boxes.
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ketotestosterone (11KT) and DHT (low nanomolar ranges) (Rege
et al., 2013). The adrenal thus secretes only very low amounts of
active androgens, but mainly androgen precursors that are acti-
vated in peripheral tissues.
It should be noted that adrenal C19 steroid production is initi-
ated during adrenarche, a pre-pubertal event (approximately age 8
in girls and 9 in boys (Idkowiak et al., 2011)) unique to humans and
higher primates (Abbott and Bird, 2009; Arlt et al., 2002; Auchusand Rainey, 2004; Miller, 2008). Adrenarche is due to the devel-
opment of the zona reticulariswhich is characterised by an increase
in the expression of CYB5A (encoding cytochrome b5) and SULT2A1,
and a decrease in the expression of HSD3B2, which in combination
favours the biosynthesis of DHEA and DHEAS (Bird, 2012; Gell et al.,
1996; Nakamura et al., 2009a). It is only after adrenarche that high
levels of C19 androgen precursors are available for peripheral acti-
vation and adrenarche thus represents the onset of signiﬁcant
intracrine androgen signalling in human life.
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and fourth decade of human life in both men and women after
which levels decline signiﬁcantly (Labrie et al., 1997b). Nonetheless,
80% of the circulating DHEA in postmenopausal women is of ad-
renal originwith the remainder produced by the ovary (Labrie et al.,
2011).
Importantly, the expression of CYP17A1 in adrenal of adult mice
and rat, which are frequently used as pre-clinical models for
endocrine and pharmacology studies, is minimal (Le Goascogne
et al., 1991; Mostaghel et al., 2017; Rodriguez et al., 1997). There-
fore, unlike humans, mouse and rat adrenals do not produce sig-
niﬁcant levels of androgen precursors (van Weerden et al., 1992)
which can serve as substrates for intracrine action and are therefore
not valid models for studies of human androgen intracrinology.
Furthermore, while other rodents such as hamster (Cloutier et al.,
1995) and guinea pig (Le Goascogne et al., 1991; Tremblay et al.,
1995) do produce adrenal C19 steroids due to adrenal CYP17A1
expression, CYP17A1 substrate speciﬁcity in these species is
signiﬁcantly different from that of the human enzyme (Cloutier
et al., 1997; Tremblay et al., 1995), thus limiting comparisons to
human adrenal steroidogenesis. Care should therefore be taken
when choosing clinical models for studies of C19 intracrine action.2.2. Ovarian C19 steroid biosynthesis
Ovarian steroid biosynthesis can be described by the “two-cell,
two-gonadotrophin” model: Two different cell types - granulosa
cells of the follicle and the surrounding theca cells - perform
distinct reactions due to speciﬁc enzyme expression (Fig. 3). In
addition, each cell type is differentially regulated by two pituitary
hormones e follicle stimulating hormone acting on granulosa cells
and luteinising hormone regulating both theca and granulosa cells
(Hillier et al., 1994). Granulosa cells do not express CYP17A1 and
their de-novo steroidogenic activity therefore stops at the stage of
the C21 steroids progesterone (PROG) and pregnenolone (PREG)
(Voutilainen et al., 1986). These precursors diffuse into the adjacent
theca cells, which express CYP17A1 and HSD3B2 (but express only
low levels of CYP11A1), and serve as substrates for the production of
A4 (Patel et al., 2010). A4 can either be secreted or converted to T by
AKR1C3 in the theca cells (Nelson et al., 2001), but the majority of
A4 diffuses back to the granulosa cells where it is converted to
estrone (E1), estradiol (E2) and E1-sulfate (E1S) (Miller and Auchus,
2011). 17b-hydroxysteroid dehydrogenase type 1, HSD17B1, is
limited to the granulosa cells, where it activates E1 to E2 (Nelson
et al., 2001). While the ovary is capable of de-novo steroidogene-
sis, studies have shown that it also efﬁciently makes use of DHEA of
adrenal origin for the production of androgens and oestrogens (Arlt
et al., 1999a; Haning et al., 1985; Lebbe et al., 2017). The presence of
steroid 5a-reductase type 1 (SRD5A1), aldo-keto reductase 1C2
(AKR1C2), aldo-keto reductase 1C4 (AKR1C4) and 17b-hydrox-
ysteroid dehydrogenase type 6 (HSD17B6) has also been demon-
strated for ovarian theca cells and some of those are required for
the functioning of the backdoor pathway, which produces DHT by-
passing DHEA, A4 and T, (section 5.3), (Marti et al., 2017). Ovarian
steroidogenesis commences with puberty when the onset of
hypothalamic-pituitary-gonadal signalling leads to an increase in
follicle stimulating hormone and luteinizing hormone which in
turn regulate steroidogenic activity (Herbison, 2016).While ovarian
steroidogenesis demonstrates a menstrual cycle-dependent proﬁle
in premenopausal women (Barbieri, 2014), the absence of ovarian
follicles in the postmenopausal ovary signiﬁcantly reduces the
production of oestrogens (Labrie et al., 2011). The contribution of
postmenopausal ovaries to circulating levels of active androgens is,
however, controversial (Couzinet et al., 2001; Fogle et al., 2007).2.3. Testicular C19 biosynthesis
Testicular androgen biosynthesis is carried out in the Leydig
cells and, similar to the adrenal, follows the classical D5 pathway
with only minor contribution of the D4 pathway (Fluck et al., 2003;
Sherbet et al., 2003). Due to high abundance of HSD3B2 and 17b-
hydroxysteroid dehydrogenase type 3 (HSD17B3) and the absence
of SULTs, the ﬁnal products are the 3-keto-D4 androgens A4 and T
(Fig. 4). HSD17B3 function is essential for testicular T generation
from A4 and it is the only human HSD17B isoform with an estab-
lished deﬁciency syndrome. HSD17B3 deﬁciency results in disor-
dered sex development in genetically male children (Boehmer
et al., 1999; Mendonca et al., 1999). However, the testes also ex-
press AKR1C3 and in cases of HSD17B3 deﬁciency the testes still
produce low amounts of T via this enzyme (Werner et al., 2012).
Concentrations of androgen in testicular venous blood of healthy
individuals are T (high nanomolar-low micromolar) » A4, DHEA
(medium nanomolar) (Hammond et al., 1977; Ishida et al., 1990;
Weinstein et al., 1974).
Unlike the fetal ovaries, the fetal testes have steroidogenic ac-
tivity which peaks between 11 and 17 weeks of gestation. Fetal
testicular T is essential for the development of the male internal
genitalia, while the local conversion of testicular T to DHT is
essential for the development of external genitalia taking place
between 8 and 12 weeks of gestation (Krone et al., 2007; Sobel
et al., 2004). Post-natal testicular steroidogenesis is initiated by
the onset of hypothalamic-pituitary-gonadal signalling during pu-
berty. A decline of androgens in men starting in the third decade of
life can be observed as aging results in a gradual development of
testicular failure due to a decreased number of Leydig cells and
response to hypothalamic-pituitary signalling (Beattie et al., 2015;
Golan et al., 2015). This results in a decline of circulating T con-
centrations of approximately 0.1 nmol/L per year (Camacho et al.,
2013).
3. C19 steroids in circulation
After production by the adrenal and gonads C19 steroids are
released into circulation. The concentration of these steroids that
peripheral tissue is exposed to is determined by (1) the total con-
centration of the respective C19 steroids in circulation, (2) whether
or not the speciﬁc steroid is bound to sex hormone binding globulin
(SHBG) or albumin and (3) the availability of mechanisms for
cellular inﬂux and efﬂux, although this is only relevant for conju-
gated steroids which require active transport across the cell
membrane (Giorgi and Stein, 1981).
In Table 2, we have summarized the serum concentrations of C19
steroids including androgen precursors, active androgens and their
metabolites, as determined by liquid chromatography-tandem
mass spectrometry in recent studies. In addition to the classical
C19 steroids (DHEAS, DHEA, T and A4), recent advances in mass
spectrometry-based analytical methodology have allowed for the
identiﬁcation and quantiﬁcation of non-classical androgen metab-
olites (Bloem et al., 2015). For example, we recently proﬁled clas-
sical and 11-oxygenated androgens in serum of healthy
premenopausal women and premenopausal womenwith PCOS.We
found that the 11-oxygenated androgens were the predominant C19
steroids in women with PCOS (O'Reilly et al., 2016). Similar results
were recently observed by another study which quantiﬁed
androgen levels in patients with 21-hydroxylase deﬁciency (Jones
et al., 2016; Turcu et al., 2016, 2017). Signiﬁcantly, our study in
healthy and PCOS women showed for the ﬁrst time that the
circulating levels of the active androgen 11KT were 3e4fold higher
than that of T in healthy premenopausal women (O'Reilly et al.,
2016), highlighting the important contribution of the 11-
Fig. 3. Schematic overview of sex steroid biosynthesis in the ovaries. Steps of ovarian de-novo sex steroid biosynthesis are partitioned between granulosa and theca cells, which
express differential sets of steroidogenic enzymes. Black box: active androgen; grey box: active oestrogen. Besides sex steroids, the ovaries produce high levels of PROG in the corpus
luteum after ovulation. Major pathways are indicated by bold arrows and all arrows are labelled with the major isoform of the enzyme responsible for the reaction.
Fig. 4. Schematic overview of C19 steroid biosynthesis in the testes. The testes produce C19 steroids via the classical D5 pathway in the Leydig cells. Due to abundant HSD3B2 and
HSD17B3, and the lack of aromatase, T is the major product making the testes the only steroidogenic organ secreting signiﬁcant amounts of an active androgen (black box). Major
pathways are indicated by bold arrows and arrows are labelled with the major isoform of the enzyme responsible for the reaction.
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In bothmen andwomen, ageing leads to decreases in C19 steroid
production (Damgaard-Olesen et al., 2016; Haring et al., 2012;
Trabert et al., 2016). However, for women it is unclear if this re-
sults from age-related decline of adrenal steroidogenesis or
menopause-induced functional alterations of the ovaries or from a
combination of both (Labrie et al., 2011; McConnell et al., 1998). In
men, the decline can be explained by simultaneous age-related
reductions of both adrenal and testicular androgen biosynthesis
(Beattie et al., 2015; Camacho et al., 2013; Golan et al., 2015; Labrie
et al., 1997b). Although one could easily presume that most C19
steroids in circulation are produced by steroidogenic tissues,
androgen metabolites released from peripheral tissue make a sig-
niﬁcant contribution to the circulating pool of C19 steroids and thus
highlight the importance of local androgen activation and meta-
bolism by intracrine mechanisms. The major fractions of androgen
metabolites are conjugated to facilitate their excretion. Indeed, a
recent study quantifying androgenmetabolites and their sulfo- and
glucoconjugates in serum, showed that T and DHT circulate pre-
dominantly in their unconjugated form, while their metabolites
androsterone (AST, 5a-androstan-3a-ol-17-one), epiandrosterone(5a-androstan-3b-ol-17-one, EpiAST) and 3a-adiol (5a-androstan-
3a,17b-diol) were mostly conjugated, each with speciﬁc prefer-
ences for sulfation or glucuronidation (Zang et al., 2017). It is has
previously been suggested that the sum of the circulating metab-
olites AST-glucuronide and 3a/b-adiol-glucuronide should be used
as estimates of active androgens produced in peripheral tissue
(Labrie et al., 1997b, 2003) (3b-adiol, 5a-androstan-3b,17b-diol).
Importantly, men and women show comparable concentrations of
circulating androgen metabolites (Table 2). Quantiﬁcation of
increased panels of C19 steroids including conjugated metabolites
are needed to provide further insight into the intracrine meta-
bolism and the role thereof in endocrine disorders.
It should be noted that all C19 steroid concentrations discussed
above and indicated in Table 2 refer to the total concentrations of
androgens in circulation and that this is not necessarily indicative
of the steroid concentration available for cellular uptake. The ma-
jority of unconjugated C19 steroids circulate bound to the plasma
proteins albumin or SHBG and only a small fraction (1e2%) circu-
lates in the free form which is accessible to the target tissue. These
sex steroid-binding plasma proteins therefore play a crucial role in
the regulation of androgen action (Laurent et al., 2016). Although
Table 2
Serum concentrations of C19 steroids determined by liquid chromatography tandemmass spectrometry. All concentrations are shown in nmol/L except for DHEA sulfate
(DHEAS), which are shown in the micromolar range. The details of the original studies are given in the footnotes below the table.
Androgen precursors Women Men Androgen metabolites Women Men
DHEA 4.2e11.8a 6.9e30c Androsterone (AST) 0.4e2.1c 0.9e1.9c
6.3e35.4c 15.8g 0.5 ± 0.03d 0.7 ± 0.03d
3.4 ± 0.03d 4.1 ± 0.1d AST-sulfate ndd 19 ± 1.6d
10e20j 1250e2500j
DHEA sulfate 3400e9600a 1312e14125c AST-glucuronide 28e467c 59e248c
701e8965c 5709g 89 ± 0.7d 104 ± 1.4d
3337 ± 16d 3247 ± 50d 2.1e170e 86e150h
4300e5400j EpiAST 0.6 ± 0.03d 0.3 ± 0.02d
A4 3.3e9.2a 2.3e5.5c EpiAST-sulfate 123±3d 105 ± 3.2d
1.2e2.82b 3.64g 500e850j
1.1e8.7c EpiAST-glucuronide 78 ± 0.4d 76 ± 1.3d
5-androstenediol (5-diol) 1.5 ± 0.07d 1.7 ± 0.2d 3a-androstanediol
(3a-adiol)
nqd 0.2 ± 0.02d
5-diol-sulfate 215 ± 21d 178 ± 10d 3a-adiol-sulfate ndd ndd
250e500j 3a-adiol-3-glucuronide 0.6e8.4c 1.3e6.7c
5a-androstanedione 0.5e2.6c 1.0e1.5c 0.5e9.2e 2.0e3.8h
11OHA4 4.9e12.5a 2.3e5.1i 3a-adiol-17-glucuronide 0.3e10c 6.2e8.8c
11KA4 2e3.9a 0.7e1.4i 0.5e12e 5.4e11h
11OHT 0.1e0.3a 0.3e0.7i DHEA-glucuronide 0.9 ± 0.001d 0.7 ± 0.03d
7aOH-DHEA 0.08e1.4f
Active Androgens 7bOH-DHEA 0.08e0.9f
T 0.2e0.5a 7.4e14c 7-oxo-DHEA 0.03e0.6f
0.58e1.1b 16.85g 16OH-DHEA-sulfate 100e200j
0.4e4.1c 15.6 ± 0.6d T-sulfate ndd ndd
1.1 ± 0.09d 10e20j T-glucuronide 0.8 ± 0.02d 26.5 ± 0.1d
Calculated free T 0.0056e0.0122b 0.3780g DHT-sulfate 0.3e2.7c 2.5e3.5c
DHT 0.2e0.9c 0.9e2c ndd ndd
0.4e0.01d 1.2 ± 0.09d DHT-glucuronide ndd ndd
11KT 1.2e1.8a 1.0e2.6i 5-diol-glucuronide nqd nqd
a O'Reilly et al. (2016), interquartile range, n ¼ 49, age interquartile range 23e32.
b Haring et al. (2012), interquartile range, n ¼ 985, age 20-80.
c Trabert et al. (2016), min-max, pre- and postmenopausal women, n ¼ 15.
d Zang et al. (2017), mean ± standard deviation for triplicate of pooled commercial serum.
e Labrie et al. (2006), min-max, pre- and postmenopausal women, n ¼ 424.
f Ke et al. (2016), min-max, pre- and postmenopausal women, n ¼ 34.
g Damgaard-Olesen et al. (2016), geometric mean, n ¼ 72, age 30-<40.
h Vandenput et al. (2007), interquartile range, n ¼ 1086, age interquartile range 18.4e19.3.
i Turcu et al. (2016), interquartile range, combined values for 19 men and 19 women, age 3-59.
j Sanchez-Guijo et al. (2016), interquartile range estimated from Fig. 2, n ¼ 60, age range 18e60.
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ranges), it makes a signiﬁcant contribution to steroid binding due to
its high abundance (Dunn et al., 1981). In contrast, SHBG binds sex
steroids (including active androgens, oestrogens, precursors and
metabolites (Avvakumov et al., 2010; Cherkasov et al., 2008; Dunn
et al., 1981; Grishkovskaya et al., 2002)) with high speciﬁcity and
afﬁnity (nanomolar ranges) (reviewed in (Hammond, 2016)).
Abnormal levels of SHBG and mutations altering the afﬁnity for its
ligands are associatedwith androgen excess and a PCOS phenotype,
but have also been implicated in the pathogenesis of cancer and
metabolic dysfunction (Hammond, 2016; Hogeveen et al., 2002).
It is therefore preferable to consider the bioactive fraction in
addition to total concentrations when considering the bioactivity of
circulating androgens. Several indirect (mathematical) and direct
(experimental) approaches can be used (Vermeulen et al., 1999).
The “free fraction” (non protein-bound fraction) and the
“bioavailable fraction” (unbound and albumin-bound fractions) can
be estimated by calculations using total androgen, albumin and
SHBG concentrations. The “free androgen index” is deﬁned as (total
T*100)/SHBG. Alternatively, free T concentrations can be measured
by equilibrium dialysis and the non SHBG-bound fraction can be
determined by differential ammonium sulfate precipitation. Free T
concentrations usually range around 1e2% of total T and are also
age-dependent in women (Haring et al., 2012) and men (Camacho
et al., 2013; DamgaardeOlesen et al., 2016). To date, the binding of
11-oxygenated androgens to SHBG and albumin has not beeninvestigated. The fraction of free 11KT relative to that of T is
therefore unknown and needs to be determined to gain further
insight into the potential physiological role of this potent androgen.
Interestingly, DHEA and 5-diol can be acylated with fatty acids
by plasma lecithin:cholesterol acyltransferase located on high
density lipoproteins (Jones and James, 1985; Lavallee et al., 1996).
The C19 steroid fatty acid ester can then be transferred to other li-
poproteins. DHEA-fatty acid esters can be taken up by peripheral
cells via lipoprotein receptors (Lavallee et al., 1996; Roy and
Belanger, 1989). Circulating DHEA-fatty acids have been shown to
account for ~9% of total DHEA in serum (Wang et al., 2011).4. C19 steroid metabolism in peripheral target tissues e
principles of intracrine androgen activation and inactivation
4.1. Cellular uptake and deconjugation
Circulating, bioavailable androgens and their precursors must
cross the plasma membrane of target cells to be (1)metabolised by
enzymes that are located intracellularly in the cytosol ormembrane
of the endoplasmic reticulum and/or (2) to activate the AR, which is
localised in the cytosol prior to activation by a suitable ligand.
While unconjugated steroids can freely diffuse across the mem-
brane due to their hydrophobic nature, steroid conjugates (sulfates
and glucuronides) are hydrophilic and require active transport
mechanisms by transmembrane proteins (Giorgi and Stein, 1981).
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steroid can be metabolised and or interact with its receptor.
Organic anion-transporting polypeptides (OATPs) belong to the
solute carrier organic anion (SLCO) transporter gene superfamily
and are the primary transporters for the inﬂux of conjugated ste-
roids, while multi drug resistant (MDR) proteins belonging to the
ATP-binding cassette (ABC) transporters are the primary trans-
porters for the efﬂux of conjugated steroids (Deeley et al., 2006;
Mueller et al., 2015). The access of a conjugated steroid to a spe-
ciﬁc cell is determined by (1) the expression level of transporters in
combination with (2) the substrate speciﬁcity and (3) the transport
kinetics of the respective transporters. Speciﬁc OATPs involved in
DHEAS uptake are overexpressed in prostate cancer, leading to an
increased intracellular availability of androgen precursors (Wright
et al., 2011) and OATP polymorphisms are associated with time to
progression during androgen deprivation therapy (Yang et al.,
2011). Knock down of OATPs have also been shown to reduce the
DHEAS-stimulated proliferation of prostate cancer cell lines
(Arakawa et al., 2012). Once transported across the plasma mem-
brane, a steroid sulfate ester is hydrolysed by steroid sulfatase (STS),
with maintenance of stereo conﬁguration yielding the respective
hydroxysteroid that is subsequently accessible for enzymatic con-
versions or can exert biological functions (Hobkirk, 1993). STS is a
membrane-bound enzyme on the luminal side of the endoplasmic
reticulum (Ghosh, 2007) and ubiquitously expressed in all human
tissues (Reed et al., 2005). Because of the high concentrations of
circulating DHEAS one might assume that STS is a main gate keeper
of peripheral androgen metabolism and action. However, while
administration of DHEA yields signiﬁcant increases in both DHEAS
and active androgens (Arlt et al., 1998, 1999b), the administration of
DHEAS does not result in any increase of DHEA and downstream
androgens in healthy adults (Hammer et al., 2005). By contrast,
patients with STS deﬁciency due to mutation show only a rather
mild clinical phenotype with ichthyosis due to the accumulation of
sulfated steroids in the skin. They present with a decreased DHEA/
DHEAS ratio, which increases to normal levels after puberty, and a
slightly increased androgen activation rate as peripheral 5a-
reductase activity seems to compensate for the loss of STS function
(Idkowiak et al., 2016). STS may therefore rather function as a ﬁne-
tuning mechanism for intracellular free steroids. However, STS
activity is upregulated in several types of cancer (reviewed in
(Mueller et al., 2015)) and has been proposed as drug target in
hormone-dependent breast, prostate and endometrial cancers to
prevent local oestrogen (including 5-diol, which has oestrogenic
effects) and androgen formation from estrone sulfate, DHEAS and
5-diol-sufate. This mechanism has recently been shown to be of
relevance also for colon cancer (Gilligan et al., 2017). The potential
of STS inhibition has been evaluated in promising clinical trials
(Geisler et al., 2011; Purohit and Foster, 2012; Thomas and Potter,
2015).
4.2. Principles of intracrine androgen steroid metabolism
After cellular inﬂux, an androgen precursor steroid is enzy-
matically activated by cell-speciﬁc enzymes and pathways before
exerting its effect via the AR. Active androgens are subsequently
inactivated enzymatically prior to being released from the cell for
excretion. This concept of hormone action is termed “intra-
crinology” and is distinct from the classical concept of “endocri-
nology” with a designated gland secreting active hormones into
circulation exerting direct effects on receptors in target tissues.
Intracrinology is deﬁned by the following principles: (1) Receptor
(AR in case of androgens) and hormone precursors metabolising
enzymes are co-expressed in the same cell; (2) an inactive hormone
precursor (e.g. DHEAS, DHEA, A4, 11OHA4) is taken up fromcirculation (s autocrinology); (3) each cell determines the amount
of the active hormone (e.g. T, DHT, 11KT, 11KDHT) produced intra-
cellularly by a speciﬁc set of enzymes; (4) several enzymatic steps
are potentially involved in the production of the active hormone
and represent different levels of regulation; (5) the hormone is
enzymatically inactivated in the same cell prior to efﬂux; (6) no
signiﬁcant amount of active hormones are released from the cell
into the extracellular space (s paracrinology) or circulation (s
endocrinology) to prevent a systemic excess of active hormones
(Labrie, 1991; Labrie et al., 1997a). Signiﬁcantly, the metabolism of
DHEA to active androgens reaches saturation with increasing
circulating concentrations of DHEA, thereby protecting peripheral
tissues from increased intracellular levels of androgens which may
result from pathologically increased biosynthesis of androgen
precursors in the adrenal (Labrie et al., 2007). Dysregulation of
intracrine pathways can result from (1) alterations of expression
leading to effects speciﬁc for the respective tissue or (2)mutations/
polymorphisms of involved enzymes leading to systemic effects;
and can be associated with metabolic dysfunction or sex steroid-
dependent cancer as discussed below.
4.3. Enzymes involved in intracrine androgen metabolism
Enzymatically catalysed reactions involved in the intracrine
metabolism of C19 steroids include hydrolysis of sulfate esters,
oxidation of the 3b-hydroxyl followed by D54-isomerisation, 11b-
oxidation/reduction, 17b-oxidation/reduction, stereoselective 5a-
or 5b-reduction of the D4-double bond, reduction of the 3-keto
group, sulfation and glucuronidation of accessible hydroxyl
groups. Additionally, C19 steroids can serve as substrates for A-ring
aromatisation yielding estrogens. HSD3B enzymes introduce the 3-
keto-D4 motif into precursor androgens such as DHEA and 5-diol,
while enzymes with reductive 17bHSD function convert the 17-
keto group common in androgen precursors to a 17b-hydroxyl
group. These two motifs (3-keto-D4 and 17b-hydroxyl) are shared
by all active androgens (Fig. 5). In contrast to the adrenal and
gonadal isoform, HSD3B2, which when deﬁcient causes a variant of
congenital adrenal hyperplasia, mutations in human HSD3B1,
which is almost exclusively expressed in peripheral tissues and
placenta (Labrie et al., 1992; Simard et al., 2005), are not known,
probably as they would prevent placental PROG production during
pregnancy (Miller and Auchus, 2011). AKR1C3 (HSD17B5) has been
suggested to make the major contribution to peripheral A4 acti-
vation by conversion to T (Miller and Auchus, 2011). Certain poly-
morphisms of AKR1C3 are associated with PCOS and increased T
levels in women (Ju et al., 2015). AKR1C3 is also overexpressed in
prostate cancer, presumably promoting cancer progression by
increasing intratumoral androgen levels (Adeniji et al., 2013; Fung
et al., 2006).
Enzymes with 5a-reductase activity can reduce the D4-double
bond which, in the presence of the 3-keto and 17b-hydroxyl, leads
to maximum androgen potential as is observed for DHT and
11KDHT (Pretorius et al., 2016). Systemic upregulation of 5a-
reductase activity is observed in women with PCOS leading to
enhanced glucocorticoid clearance and enhanced androgen acti-
vation in peripheral tissues (Fassnacht et al., 2003; Stewart et al.,
1990; Vassiliadi et al., 2009), which is associated with metabolic
dysfunction (Conway et al., 2014; O'Reilly et al., 2014b). SRD5A2
encoding steroid 5a-reductase type 2 (SRD5A2) is expressed in
male reproductive tissues (Thigpen et al., 1993) and its disruption
leads to the impairment of local DHT formation and in consequence
disordered sex development in 46, XY individuals (Okeigwe and
Kuohung, 2014; Wilson et al., 1993). The sequence of androgen
activation is substrate speciﬁc as SRD5A enzymes can also reduce
the D4-double bond of 17-keto steroids prior to their 17b-reduction.
Fig. 5. Principles of androgen activation and inactivation. All active androgens (T, DHT, 11KT and 11KDHT) share the 3-keto-D4 and 17b-hydroxyl motifs (shown in the black
frame, taking example of T). Solid arrows indicate activation reactions, while dashed arrows represent inactivating reactions and preparation for excretion. 5a-reduction is necessary
to achieve maximum AR activation (DHT, 11KDHT). The 11-oxygenated androgens also require the conversion of the 11b-hydroxyl to the 11-ketone in order to obtain maximal
activity (11KT and 11KDHT; dotted inset).
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via the 5a-reduction of A4 to 5a-androstanedione (5a-dione, 5a-
androstane-3,17-dione), followed by the conversion of 5a-dione to
DHT (Chang et al., 2011' Luu-The and Labrie, 2010; Samson et al.,
2010) (Fig. 6). Conversely, our group has shown that the activa-
tion of 11KA4 (D4, 17-keto) proceeds by the 17b-reduction to 11KT,
followed by 5a-reduction to 11KDHT (5a,17b) (Pretorius et al., 2017)
(Fig. 6). It should also be noted that the expression of HSD11B2,
which encodes the oxidative HSD11B isoform, is required for the
activation of 11OHA4, which is the primary 11-oxygenated C19
androgen precursor in circulation (Rege et al., 2013; Storbeck et al.,
2013; Swart et al., 2013) (Table 2).
Fatty acid esters of androgen precursors can be hydrolysed
intracellularly releasing the free steroid and fatty acid acylation of
DHEA, 5-diol and T can take place in peripheral tissues, like adipose
tissue (Hochberg, 1998; Vihma and Tikkanen, 2011; Wang et al.,
2011, 2012).
Following activation, the resulting potent androgens are further
metabolised in the target cell of androgen action, yielding inactive
metabolites. This metabolism prevents the over-activation of the
AR as well as the release of signiﬁcant amounts of the activated
androgens back into circulation (Labrie, 1991). As such the effect of
the androgen precursors is maintained within a given target tissue
and does not result in a systemic effect (Labrie, 1991; Labrie et al.,
1997a). The inactivation reactions can be classiﬁed into phase 1
(oxidations and reductions at position 3a/b-, 5a/b, 11b, 17b) and
phase 2 metabolism (conjugation of 3/17-hydroxyls), according to
the classical two-phase model of detoxiﬁcation mechanisms
(Williams, 1959). The main route of androgen inactivation proceeds
(1) via the irreversible 5a/b-reduction of the 3-keto-D4 species,followed by (2) the 3a/b-reduction of the 5a/b-reduced androgen.
These stepsmay be followed by (3) the conjugation of the emerging
3-hydroxyl or the 17-hydroxyl (Fig. 5). Conjugation can also occur at
the 17b-hydroxyl position and can occur prior to 3a/b- and 5a/b-
reduction. Both 5a/b-reduction and glucuronidation are irrevers-
ible reactions and thus shift the equilibrium towards inactivation.
Unlike 5a-reduction, 5b-reduction inactivates classical AR sig-
nalling capability of an androgen. Steroid 5b-reductase is a soluble
aldo-keto-reductase enzyme (AKR1D1) and is presumed to be the
only human enzyme catalysing the 5b-reduction of C18, C19, C21, and
C27 3-keto-D4 steroids and bile acids (Chen et al., 2011; Chen and
Penning, 2014; Kondo et al., 1994). It is mainly expressed in the
liver (Charbonneau and The, 2001; Wu et al., 2009) and 5b-
reduction therefore plays only a minor role in other tissues. 5a-
reduced metabolites are therefore conclusively more indicative for
peripheral androgen metabolism than 5b-reduced metabolites,
which are more likely to be of hepatic origin (Chen and Penning,
2014).
The 3a- and 3b-reduction of 5a/b -reduced androgens is carried
out by members of the AKR1C family, which exert 3a- and 3bHSD
activities (Penning et al., 2000, 2004; Steckelbroeck et al., 2004),
with different isoforms showing distinct a/b preferences
(Steckelbroeck et al., 2004). 5b-reduced androgens are preferably
reduced to their 3a-hydroxyl derivative (Jin et al., 2011) making 3b/
5b-reduced androgens rare. “Back conversion” of a 3a-reduced
androgen to their 3-keto forms (e.g. 3a-adiol to DHT) are possible in
presence of an oxidative 3aHSD; 3a- and 3b-hydroxyls can also be
interconverted by epimerase activity (Bauman et al., 2006;
Belyaeva et al., 2007; Penning et al., 2004).
Androgen metabolites with a 3a/b- and/or 17b-hydroxyl can be
Fig. 6. Schematic of intracrine pathways for the production of active androgens from C19 precursors. Circulating C19 steroids (grey boxes) can be converted to active androgens
(black boxes) in peripheral tissues exhibiting the required enzymatic activities. Activities are indicated next to each arrow. Pathways of peripheral androgen activation are recurring
and distinct from pathways of de-novo biosynthesis (Figs. 2e4). 17aHP, 5a-pregnan-3a,17a-diol-20-one; Pdione, 5a-pregnan-17a-ol-3,20-one.
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glucuronosyl group or a sulfate. Conjugation of the 11b-hydroxyl
has not been described, thus suggesting that it may not be acces-
sible to the UDP-glucuronosyl transferases (UGT) or SULT enzymes.
Glucuronidation of C19 steroids is performed by members of the
UGT2B subfamily with different substrate preferences and regio-
selectivity (3 and/or 17), which are expressed in the liver and
androgen-sensitive tissues (Belanger et al., 2003). UGTs are
microsomal, membrane-bound enzymes catalysing the transfer of
the glucuronic acid group of uridine diphospho-glucuronic acid to a
functional group (here a hydroxyl) of a speciﬁc substrate. As
opposed to sulfation, glucuronidation is irreversible and ultimately
inactivates the androgen and initiates its renal excretion by
increasing polarity and water solubility of the molecule (Belanger
et al., 2003). UGT gene variants are associated with serum con-
centrations of glucuronidated androgen metabolites (Grant et al.,
2013) and gene deletions of individual UGTs signiﬁcantly reduce
these concentrations (Nadeau et al., 2011), which is reﬂected in
alterations of urinary T metabolite excretion (Jakobsson et al.,
2006). Due to differential expression and regioselectivity of UGTs
the comparative study of 3a-adiol-3-glucuronide and 3a-adiol-17-
glucuronide can give insight in tissue-speciﬁc function of the
different UGTs (Barbier and Belanger, 2008; Belanger et al., 2003).
As SULT2A1 expression is mainly limited to the liver, adrenal, colon
and kidney (Riches et al., 2009), glucuronidation is the more
important conjugation reaction in androgen target tissue. The two
SULT2B1 isoforms contribute to androgen metabolite sulfation in
prostate, placenta, lung and skin (Falany et al., 2006).
Androgens may also be converted to oestrogens (C18 steroids
with aromatic A-ring) in tissues expressing CYP19A1 encoding cy-
tochrome P450 aromatase (CYP19A1). CYP19A1 is a microsomal
enzyme catalysing a 3-step C10-C19 demethylation/A-ring aroma-
tisation of several C19 steroids via 19-hydroxy- and 19-aldehyd-
intermediates (Beusen et al., 1987; Covey et al., 1987). A4, T, their
16a-hydroxy derivatives and 16bOH-A4 are all substrates for this
enzyme (Harada, 1988; Neunzig et al., 2017). Sites of extra-ovarian
CYP19A1 expression are placenta, adipose tissue, brain, bone and
vasculature (Simpson et al., 2002). The intracrine production ofoestrogens from androgen precursors is an essential source of
oestrogens in postmenopausal women (Simpson, 2003).
The cell-speciﬁc pathways are determined by the respective set
of enzymes expressed, their substrate speciﬁcities and enzymatic
efﬁciencies, and the intracellular availability of free substrates.
Directionality is driven by (1) irreversible reactions (5a/b-reduc-
tion, P450 oxidation, 3b-hydroxyl oxidation/D54 isomerisation,
glucuronidation), (2) the relative expression levels of reductive and
oxidative HSD enzymes and (3) the redox status of the cell which
contributes to HSD directionality (Agarwal and Auchus, 2005).
It should again be noted that care should be taken when using
animal models to study intracrinology as the enzyme isoforms vary
greatly between species. A good example are the signiﬁcant dif-
ferences between rodent and human HSD3B and HSD17B enzymes.
Rodents have multiple isoforms of HSD3B, while humans have only
two. Furthermore, unlike the human enzymes, some rodent HSD3B
isoforms have additional 17bHSD activity (de Launoit et al., 1992;
Payne et al., 1995; Simard et al., 1995). Similarly, HSD17B en-
zymes have different isoforms (Marchais-Oberwinkler et al., 2011;
Moeller and Adamski, 2009), substrate speciﬁcities (Blanchard
and Luu-The, 2007; Puranen et al., 1997) and tissue distribution
(Martel et al., 1992) in humans and rodents. Enzymes with 3bHSD
and 17bHSD activity are also insufﬁciently characterised in non-
human primate models, therefore not allowing for comparisons
to human intracrine systems to be drawn.5. Pathways of peripheral androgen activation
5.1. The classical androgen biosynthesis pathway
Circulating T, generated from DHEA via A4, can be further acti-
vated to DHT in peripheral tissue with 5a-reductase activity. While
SRD5A1 catalyses the majority of hepatic 5a-reduction, SRD5A2 in
male reproductive tissues (Thigpen et al., 1993) and its deﬁciency
leads to disorders of male sexual differentiation (Wilson et al.,
1993). Circulating C19 precursors can also be activated by 3bHSD
and reductive 17bHSD activity leading to the formation of T.
However, the classical pathway via T plays only a minor role in the
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It is worth noting that a third isoform of steroid 5a-reductase
(SRD5A3) has been described (Cantagrel et al., 2010; Mitsiades
et al., 2012; Uemura et al., 2008) and is expressed in peripheral
tissue (Yamana et al., 2010). While the role of SRD5A3 in androgen
metabolism is yet to be fully elucidated, SRD5A3 has conﬁrmed
polyprenol reductase activity and has been shown to be involved in
N-linked glycosylation with SRD5A3 mutations being linked to
congenital disorders of glycosylation (Cantagrel et al., 2010).
5.2. The alternate 5a-dione pathway
The alternate 5a-androstanedione pathway bypasses T as in-
termediate of DHT biosynthesis (Fig. 6). A4 is ﬁrst 5a-reduced by
SRD5A1, yielding 5a-dione due to the higher afﬁnity and catalytic
efﬁciency of SRD5A1 for A4 than for T (Andersson and Russell, 1990;
Russell and Wilson, 1994; Sugimoto et al., 1995), which is followed
by the conversion of 5a-dione to DHT by reduction of the 17-ketone
(Chang et al., 2011; Luu-The and Labrie, 2010; Samson et al., 2010).
This pathway is not present in the adrenal or gonads, but plays the
major role for peripheral DHT generation from circulating pre-
cursors other than T (Luu-The and Labrie, 2010). It has especially
been shown to be an essential pathway for intratumoral DHT
production from adrenal androgen precursors in CRPC when
circulating levels of T are signiﬁcantly reduced by physical or
chemical castration (Chang et al., 2011; Shariﬁ and Auchus, 2012).
5.3. The backdoor pathway
Another alternative pathway to DHT is the so-called “backdoor”
pathway which by-passes T, A4 and DHEA. In this pathway, C21
precursors, mainly 17a-hydroxyprogesterone (17OHPROG) but also
progesterone, are substrates for (1) 5a-reductase activity and (2) a
reductive 3aHSD activity. This leads to generation of 5a17-
hydroxypregnanolone (5a17HP; 5a-pregnan-3a,17a-diol-20-one)
in the case of 17OHPROG, which then (3) undergoes the 17,20-lyase
reaction to androsterone (AST) (Auchus, 2004). Reductive 17bHSD
activity (4) and oxidative 3aHSD activity (5) subsequently lead to
the conversion of AST to DHT (Fig. 6). The initial 5a- and 3a-re-
ductions support the C17-C20 side-chain cleavage by delivering
5a17HP, which is the best substrate for the 17,20-lyase activity of
CYP17A1 and whose cleavage is not dependent on cytochrome b5
(Gupta et al., 2003). In humans, the backdoor pathway is relevant in
pathological conditions when 17OHPROG accumulates, such as in
congenital adrenal hyperplasia due to cytochrome P450 oxidore-
ductase deﬁciency (PORD) or 21-hydroxylase deﬁciency (Arlt et al.,
2004; Homma et al., 2006; Kamrath et al., 2012; Krone et al., 2012;
Miller and Auchus, 2011). In PORD, the alternative pathway can
result in sufﬁcient virilisation of affected 46, XY individuals in the
prenatal period, despite the complete disruption of the classic
androgen pathway, as CYP17A1 will still convert 5a17HP towards
DHT but no longer 17a-hydroxy-pregnenolone and 17OHPROG to
DHEA and A4, respectively.
5.4. The 11-oxygenated androgen pathways
Pathways for the generation of active 11-oxygenated androgens
(11KT and 11KDHT) start with the CYP11B1 catalysed 11b-hydrox-
ylation of A4 and T (Swart et al., 2013). The adrenal is the only
source for 11-oxygenated C19 precursors due to the adrenal speciﬁc
expression of CYP11B1. It is not surprising that 11OHA4 is the
predominant 11-oxygenated C19 steroid produced as the adrenal
produces signiﬁcantly more A4 than T (Rege et al., 2013). Both11OHA4 and 11OHT are released into circulation and can subse-
quently be activated in peripheral tissues (Fig. 6). Both steroids can
be converted to their respective 11-keto forms by HSD11B2. While
11OHA4 is not a substrate for reduction of the 17b-hydroxyl, 11KA4
is readily converted to 11KT which can be 5a-reduced to 11KDHT
(Bloem et al., 2013; Pretorius et al., 2017; Swart and Storbeck, 2015).
While 11OHT and 11OHDHT represent partial AR agonists, 11KT and
11KDHT are full agonists with the same AR activating potential as T
and DHT, respectively (Pretorius et al., 2016; Storbeck et al., 2013).
The presence of the reductive enzyme HSD11B1, in some peripheral
tissues may therefore prevent the activation of 11OHA4 and catal-
yse the inactivation of 11KA4 and 11KT, which are also in circula-
tion, albeit at signiﬁcantly lower levels than 11OHA4 (O'Reilly et al.,
2016). The relative activities of HSD11B2 and HSD11B1 are there-
fore critical in determining the activity of 11-oxygenated androgens
in peripheral tissue. This additional level of regulation suggests that
the 11-oxygenated androgens have a more select number of target
tissues in comparison to the classical androgens.6. Directionality of biosynthetic steps, phase 1 metabolism
and conjugation
The classical concepts of androgen biosynthesis andmetabolism
suggest that conjugation is the ﬁnal step of a pathway. For example,
DHEA is sulfated by SULT2A1 to DHEAS at the end of adrenal
androgen biosynthesis, and detoxiﬁcation is achieved by sequential
phase 1 and 2 metabolism; with the phase 1 reaction sometimes
even being required to allow a phase 2-reaction, e.g. the reduction
of the 3-ketone to give a hydroxyl accessible for conjugation.
However, increasing evidence suggests that this directionality is
not obligate.
A small number of enzymatic pathways have been described
that can directly interconvert sulfated steroids and proceed anal-
ogously to the biosynthetic pathways of free androgens. DHEAS has
been shown to be converted to 5-diol-3b-sulfate by 17bHSD activity
present in human testes (Ruokonen, 1978) and T-sulfate has been
shown to be converted to estradiol-17-sulfate by CYP19A1 in hu-
man placental microsomes (Satoh et al., 1992). Furthermore,
CYP17A1 has been shown to be able to 17a-hydroxylate PREG-
sulfate in a recombinant human cell line, but could not catalyse
the subsequent 17,20-lyase reaction (Neunzig et al., 2014). Inter-
estingly, recombinant HSD3B2 has been shown to have steroid
sulfatase activity converting PREG-sulfate to PREG (Sanchez-Guijo
et al., 2016). Although a physiological meaning of these reactions
has not been established, their discovery clearly shows an under-
estimated role of sulfated steroids in steroid metabolism and
action.
Interestingly, phase 2 reactions can precede phase 1 reactions
during androgen inactivation. After glucuronidation and sulfation
androgen metabolites can be metabolised by AKR1C subfamily
members, e.g. DHT-17-glucuronide/sulfate to 3a-adiol-17-
glucuronide/sulfate with kinetic parameters even indicating a
preference of the 17-glucuronidation preceding the 3a-reduction
(Jin et al., 2009; Penning et al., 2010). Finally, foetal CYP3A7 has
been shown to catalyse the 16a-hydroxylation of DHEAS (Ohmori
et al., 1998).7. Intracrinology in metabolic target tissues
7.1. Adipose tissue
Adipose tissue expresses isoforms of all enzymes required for
the activation of androgens from circulating precursors (STS,
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AKR1C3 with involvement in androgen activation, and SRD5A1) as
well as their subsequent inactivation (reductive 3aHSDs (mainly
AKR1C2), UGT2B15 and UGT2B17) (Blouin et al., 2009b; O'Reilly
et al., 2014a; Tchernof et al., 2015). The activation of androgens
within adipocytes has been shown to regulate proliferation and
differentiation, insulin sensitivity, adipokine signalling and lipid
metabolism (O'Reilly et al., 2014a). While functional studies of
androgen conversion within adipocytes are fragmentary, there is
evidence for the importance of HSDs from the AKR1C subfamily.
AKR1C1 (predominant 20aHSD with low reductive 3aHSD activity),
AKR1C2 (reductive 3aHSD activity) and AKR1C3 (reductive 17bHSD
activity) show the highest expression levels of all steroid convert-
ing enzymes expressed in adipocytes of women and men (Blouin
et al., 2009b) and their expression and activity correlates with
obesity in women and men (Blouin et al., 2005, 2006). AKR1C3
expression has been shown to decrease with weight loss in female
subcutaneous adipose tissue (Quinkler et al., 2004). AKR1C3
(reductive 17bHSD, A4/T) and AKR1C2 (reductive 3aHSD,
DHT/3a-adiol) activity has been shown for adipocytes from both
men and women with higher activity of the inactivating 3aHSD
(Blouin et al., 2003, 2006). The correlation of both activating and
inactivating enzymes with obesity indicates an increased local
production and metabolic clearance of androgens highlighting the
importance of adipose tissue intracrinology in obesity. Measure-
ments of sex steroid levels in adipose tissue of obese men (ng/g)
revealed general levels of DHEA > A4  T > E1 > DHT with differ-
ences between omental and subcutaneous depots (Belanger et al.,
2006). The approximation of A4 and T levels compared to circu-
lating concentrations highlights the importance of reductive
17bHSD activity (AKR1C3) converting A4 to T local androgen load
(Belanger et al., 2006). Importantly, AKR1C3 expression and activity
increases with the differentiation of preadipocytes to mature adi-
pocytes and the interconversion of A4 and T is shifted in favour of T
generation only in mature adipocytes (Quinkler et al., 2004). The
expression of UGTs in adipose tissue (Tchernof et al., 1999) and the
correlation of plasma 3a-adiol glucuronide with fat mass in men
(Tchernof et al., 1997) suggest phase 2 metabolism as ﬁnal step of
androgen inactivation in adipocytes.
Androgen excess is recognised as the major determinant driving
metabolic dysfunction observed in women with PCOS (Conway
et al., 2014) and the degree of androgen excess correlates with
the severity of insulin resistance in PCOS (O'Reilly et al., 2014b). We
have recently shown that serum T levels correlated with BMI in
both healthy women andwomenwith PCOS. This data supports the
AKR1C3 catalysed conversion of A4 to T within adipose tissue and
further suggests that not all T produced within adipocytes is inac-
tivated, but that a portion of the T is also released in circulation.
Interestingly, we also showed that in the same cohort 11KT did not
correlate with BMI, which is not surprising given that HSD11B1 is
present in adipose tissue, and not HSD11B2. This prevents the
conversion of 11OHA4 to 11KA4, which is a prerequisite for the
subsequent conversion of 11KA4 to 11KT by AKR1C3 (O'Reilly et al.,
2016).
Aromatisation of androgens to oestrogens takes place in male
and female adipose tissue (Longcope et al., 1978; McTernan et al.,
2000) and increased aromatization has been proposed as a major
mechanism leading to obesity-induced male androgen deﬁciency
(Cohen, 1999). The expression of aromatase in adipose tissue has
also been shown to be elevated in postmenopausal women (Bulun
and Simpson, 1994) and as such adipose tissue is an important
source of oestrogen in these women (Simpson, 2003). The effects of
androgens on adipocyte function and the expression pattern of
metabolizing enzymes are deﬁned by sex, fat depot localisation and
menopause status (Blouin et al., 2009a; O'Reilly et al., 2014a;Quinkler et al., 2004).
7.2. Skeletal muscle
Androgens exhibit beneﬁcial effects on skeletal muscle function
supporting myogenic differentiation and improving protein syn-
thesis, lipid oxidation, insulin sensitivity, glucose utilisation and
mitochondrial function (Kelly and Jones, 2015). Furthermore,
muscle regeneration and recovery is supported by the androgen-
dependent regulation of muscle satellite cells (MacKrell et al.,
2015). As a consequence of their higher circulating T levels, men
have higher lean mass then women (Wells, 2007). Muscle cells
exhibit 3bHSD, reductive 17bHSD and 5a-reductase activity
resulting in the activation of DHEA to T and DHT. Expression de-
creases during ageing and can be rescued by resistance training
(Sato et al., 2014a, 2014b). The production of T from A4 by AKR1C3
has been proposed to be the essential step of androgen activation in
muscle (Lin et al., 1997; Longcope and Fineberg, 1985; Luu-The and
Labrie, 2010), with the further conversion of T to DHT seeming to
play only aminor role as there is no clarity regarding the expression
of SRD5A isoforms (Luu-The and Labrie, 2010). A4 and T can also be
aromatised in skeletal muscle (Longcope et al., 1978; Matsumine
et al., 1986), with low activity and expression of aromatase. How-
ever, as skeletal muscle represents a major part of the human body,
its contribution to systemic oestrogen levels has been proposed to
be signiﬁcant in men and post-menopausal women (Larionov et al.,
2003). 3a-reduction and phase 2 metabolism in skeletal muscle has
not been studied to date and the contribution of skeletal muscle to
circulating levels of active androgens cannot conclusively be ruled
out at present. No mRNA of SULT2A1 or SULT2B1 has been detected
in skeletal muscle (He et al., 2005; Luu-The et al., 1995).
7.3. Liver
7.3.1. Hepatic phase 1 metabolism
The liver catalyses extensive phase 1 and phase 2 metabolism of
xenobiotics and endogenous hormones including steroids, thereby
regulating their activity and clearance. Hepatic phase 1 metabolism
of androgens includes the following types of reactions: (1) 5a/b-
reduction of the D4-double bond followed by 3a/b-reduction of the
3-ketone; (2) oxidations by a large set of hepatic P450 enzymes; (3)
HSD reactions of 11b- and 17b-hydroxyls if available and of hy-
droxyls introduced by P450s. Fig. 7 provides a summary of reactions
catalysed by drug- and xenobiotic-metabolising liver enzymes.
The liver has high levels of the 5b-reductase AKR1D1 and pri-
marily produces 5b-reduced androgens (e.g. etiochonanolone, 5b-
androstan-3a-ol-17-one, ETIO) in contrast to peripheral tissue
which produce 5a-reduced species (Charbonneau and The, 2001;
Chen and Penning, 2014; Penning, 2010). The subsequent forma-
tion of the 3a-reduced counterpart of a 5b-reduced steroid is fav-
oured over the 3b-reduction leading to mainly 3aOH-5b-reduced
metabolites (Jin et al., 2011). Mutations of AKR1D1 lead to severely
reduced to completely absent urinary 5b-reduced steroid excretion
and hepatic failure, as AKR1D1 is essentially involved in hepatic bile
acid synthesis, but no other clinical manifestations (Gonzales et al.,
2004; Lemonde et al., 2003; Palermo et al., 2008).
Hepatic phase 1 metabolism is extremely diverse due to the
contribution of various P450 enzymes. In contrast to the steroido-
genic P450s expressed in adrenals and gonads, hepatic CYPs have a
high degree of functional plasticity on different levels: (1) genetic
variation (polymorphisms, copy number, promoter variants); (2)
variation of expression levels due to inducibility by e.g. xenobiotics;
(3) variation of activity (broad substrate speciﬁcity and thus
competition of different substrates, limited selectivity, multiple
substrate binding sites positively or negatively inﬂuencing the
Fig. 7. Overview of hepatic phase 1 and 2 metabolism of C19 steroids. Phase 1 metabolism comprises the 5a/b-reduction of the D4 double bond and the reduction of the 3-keto
group to its 3a/b-hydroxyl as well as hydroxylations and further oxidations at various positions. Phase 2 reactions consist of the conjugation of the 3- and 17-hydroxyls. 17a-
conjugates originate from Epitestosterone. The reactions shown in the ﬁgure summarize those described for T, A4 and DHEA.
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competition for their electron transfer protein cytochrome P450
reductase) (Zanger and Schwab, 2013). This leads to high inter- and
intra-individual variability in hepatic P450 enzyme activity. About a
dozen P450s of the CYP1, CYP2, CYP3 and CYP7 families can catalyse
hydroxylations with diverse regio- and stereochemistry as depicted
in Fig. 7 and summarized in a review by Niwa et al. (2015). Some of
these P450s may also catalyse an additional oxidation of a hydroxyl
to its ketone (e.g T/ A4 or 16bOH-T/ 16-keto-T). CYP3A4 is the
most abundant P450 in the liver (~30%) (Shimada et al., 1994) and
predominantly, though not exclusively, catalyses the 6b-hydroxyl-
ation of T and the 16a- and 7a-hydroxylation of DHEA (Niwa et al.,
2015).
Several HSD17B isoforms are active in the liver (Moeller and
Adamski, 2009) as well as HSD11B1, which oxidises 11-keto-ste-
roids to their 11b-hydroxyl form. HSD11B1 plays an important role
in the recycling of cortisol from its inactive metabolite cortisone
(Gathercole et al., 2013) and might therefore also be involved in the
hepatic metabolism of 11-oxygenated androgens. HSD11B1 is also
involved in the metabolism of the DHEA metabolite 7aOH-DHEA
(produced by CYP3A4 and CYP7B1) (El Kihel, 2012). It catalyses the
interconversion of 7a- and 7b-OH-DHEA via the 7-keto interme-
diate (Muller et al., 2006).
Unusual reactions leading to new T metabolites have recently
been described and include the methylation of an unknown T
metabolite, probably at a hydroxyl functional group, and the de-
methylation to C19-nor-androgens (Piper et al., 2016). The excre-
tion of 19-nor-AST has previously been described (Dehennin et al.,
1999). De-methylation may result from uncomplete C10, 19-lyase/A-
ring aromatisation reaction by CYP19A1.7.3.2. Hepatic phase 2 metabolism
Hepatic phase 2 metabolism includes glucuronidation and sul-
fation. All UGTs capable of androgen glucuronidation are expressed
at high levels in the liver (Belanger et al., 2003) leading to intensive
hepatic glucuronidation compared to other tissues (Rittmaster
et al., 1993). Conjugated metabolites are released from liver cells
into circulation by active transport. The main androgen metabolites
in circulation derived from hepatic and other peripheral meta-
bolism are 3a-adiol-3-glucuronide, 3a-adiol-17-glucuronide, AST-
glucuronide and ETIO-glucuronide with levels higher than for T.
Interestingly, the concentration of 17-keto metabolites incirculation is higher than that of the 17b-hydroxy metabolites with
AST-glucuronide and -sulfate being the most abundant (see
(Kalogera et al., 2013) for a review of LC-MS/MS based studies of
circulating androgen and their glucuronides).
Genetic variations of UGTs can change the glucuronidation ef-
ﬁciency for an androgen and alter its excretion (Piper et al., 2016).
The formation of androgen linked di-glucuronides (second glu-
curonidation occurs on the ﬁrst glucuronosyl moiety) is also
possible (Murai et al., 2005, 2006). Discrete di-glucuronidation
(conjugation at two different functional groups of the same mole-
cule) has to our knowledge not been described. Steroids are pref-
erentially glucuronidated in either 3- or 17-position depending on
the substrate and regio selectivity of the individual UGTs.
The liver also shows high SULT expression and activity
compared to other tissues, including SULT2A1 and SULT2B1
involved in androgen metabolism (Meloche and Falany, 2001;
Riches et al., 2009). The formation of distinct di-sulfates is
described for the synthetic androgen tibolone (Falany et al., 2004)
and cholesterol (Cook et al., 2009). 16a-hydroxy-DHEAS, 5-diol-
sulfate, AST-sulfate, EpiAST-sulfate can be measured in nM con-
centrations in serum of both men and women (Labrie et al., 1997b;
Sanchez-Guijo et al., 2015; Zang et al., 2017). Importantly, women
produce androgen metabolites in concentrations comparable to
that of men (Labrie et al., 1997b; Trabert et al., 2016; Zang et al.,
2017).
7.3.3. The liver as a target tissue of androgen action
Although the liver is traditionally considered only in terms of
phase 1 and phase 2 metabolism, the liver also expresses AR
turning it into a target tissue for classical androgen action. Both T
and DHT have recently been shown to increase lipogenesis in hu-
man hepatocytes of female (but not male) donors (Nasiri et al.,
2015) and androgens have been shown to play a crucial role in
the development of hepatocellular carcinoma (Kalra et al., 2008;
Kanda et al., 2014).
8. Intracrine androgen metabolism in reproductive target
tissues
8.1. Breast and endometrium
While oestrogens have essential proliferative effects on the
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expression of the AR have demonstrated both positive and negative
outcomes in breast cancer as reviewed in (Hickey et al., 2012;
McNamara and Sasano, 2015a, 2016). Both androgens and oes-
trogens are synthesised from circulating androgen precursors in
breast tissue and the homeostasis of these pathways determines
health status (McNamara and Sasano, 2015b). Aromatase inhibition
is a mainstay of postmenopausal breast cancer treatment and an
impressive model for the translation of intracrine modulation to
patient care. Androgenmetabolism in breast is however, frequently
overlooked. Numerous studies have shown that androgen levels are
higher within breast tissue than in circulation and are generally
higher in benign tissue than cancerous tissue, demonstrating the
relevance of intracrinology in breast and its dysregulation in cancer
(Stanczyk et al., 2015). It should also be noted that menopausal
status signiﬁcantly inﬂuences the intracrinology of breast tissue
(McNamara and Sasano, 2015b). Breast cancer tissue has STS,
3bHSD, reductive 17bHSD, 5a-reductase and aromatase activities
(Labrie et al., 2003; McNamara and Sasano, 2015b; Suzuki et al.,
2005) as well as 3aHSD, UGT, and SULT activity (McNamara et al.,
2013). Selective inhibition of HSD3B1 has been shown to slow
down proliferation of breast cancer cell line and might just repre-
sent an interesting drug target simultaneously tackling androgen
and oestrogen synthesis (Thomas et al., 2011). However, as with the
heterogeneous expression of steroid receptors within breast cancer
the expression of steroid metabolising enzymes is also heteroge-
neous and the speciﬁc pathways followed can therefore vary
greatly. The detailed intracrinology of breast tissue is therefore a
complex topic and beyond the scope of this review for review see
(Africander and Storbeck, 2017; Capper et al., 2016; Labrie et al.,
2003; McNamara et al., 2013; McNamara and Sasano, 2015b).
In the endometrium, intracrine production of androgens and
estrogens may be involved in regulating decidualisation (trans-
formation of endometrial stromal cells to secretory cells) and
receptivity. While aromatase activity increases during deciduali-
sation leading to an increased estrogen secretion (Gibson et al.,
2013), time-dependent changes in SDR5A1 and AKR1C3 expres-
sion alter T and DHT secretion. While T production increases and
stays elevated during decidualisation due to constantly increased
AKR1C3 levels, DHT secretion initially increases, but then decreases
with the progression of the decidualisation process following re-
ductions in SRD5A1 levels (Gibson et al., 2016).
8.2. Prostate
Androgens and in particular the intraprostatic conversion of
circulating T to DHT by SRD5A2 (Russell and Wilson, 1994) are
required for normal prostate development and function (Andersson
et al., 1991; Imperato-McGinley et al., 1974). Androgen deprivation
therapy in the form of chemical or physical castration is therefore a
preferred treatment of advanced prostate cancer. Despite initially
demonstrating excellent results the prostate cancer often remerges
as castration resistant prostate cancer, which in most cases remains
androgen dependent. While the contribution of de-novo intra-
tumoral biosynthesis to local androgens has mostly been excluded
(Hoﬂand et al., 2010), numerous studies have shown that CRPC is
dependent on the intracrine conversion of circulating androgen
precursors of adrenal origin to active androgens reviewed in
(Capper et al., 2016; Luu-The et al., 2008; Pretorius et al., 2017;
Shariﬁ and Auchus, 2012). Speciﬁcally, the alternate 5a-dione
pathway catalyses the conversion of DHEA and A4 to DHT while
bypassing T completely (Fig. 6). The ﬂux through this pathway is
due to the preference of SRD5A1, the dominant isoform expressed
in CRPC, for A4 over T, coupled to the poor efﬁciency by which
AKR1C3 converts A4 to T (Chang et al., 2011; Shariﬁ, 2012).Additionally, the back conversion of 3a-adiol to DHT by oxidative
3aHSDs has been demonstrated for prostate cancer cell lines
enabling a recycling of this DHT metabolite (Bauman et al., 2006;
Mohler et al., 2011; Rizner et al., 2003). Prostate cells also express
CYP3A4 that can inactivate T by conversion to mainly 6bOH-T (with
2b-, 15a/b- and 11b-hydroxyl side product formation (Niwa et al.,
2015)) and a decrease of CYP3A4 expression is observed in pros-
tate cancer (Fujimura et al., 2009). After 5- and 3-reduction an-
drogens are extensively glucuronidated in the prostate producing
3a-adiol-17-glucuronide and AST-3-glucuronide. Genetic varia-
tions of UGTs signiﬁcantly contribute to prostate cancer risk and
progression and there is evidence for a down-regulation of UGTs in
prostate cancer promoting intratumoral androgen accumulation
(Barbier and Belanger, 2008; Gauthier-Landry et al., 2015). Because
of the ability of prostate cancer cells to convert 3a-adiol back to
DHT its glucuronidation is of particular importance for androgen
inactivation and the regulation of cancer progression (Chouinard
et al., 2007).
Recent studies have also shown that prostate cancer cell lines
are able to metabolise the adrenal androgen precursor 11OHA4
(Storbeck et al., 2013; Swart et al., 2013; Swart and Storbeck, 2015).
Metabolism proceeds via the conversion of 11OHA4 to 11KA4 by
HSD11B2. 11KA4 is then preferentially converted to 11KT by
AKR1C3 and 11KT can then be 5a-reduced to yield 11KDHT
(Pretorius et al., 2017) (Fig. 6). Interestingly, the rate at which 11KT
and 11KDHT are inactivated by prostate cancer cell lines has been
shown to be signiﬁcantly lower than for T and DHT, suggesting that
these metabolites may remain active for longer than the classical
androgens (Pretorius et al., 2016). Signiﬁcantly, both 11KT and
11KDHT have been shown to be able to induce androgen-regulated
gene and protein expression as well as cell growth in androgen
dependent prostate cancer cell lines suggesting that these andro-
gens may play a previously overlooked, but important role in the
development and progression of CRPC (Pretorius et al., 2016).
Indeed, a recent study showed that the levels of these 11-
oxygenated androgens were higher than those of the classical an-
drogens in tissue from two patients with prostate cancer (du Toit
et al., 2017). Despite the promising results obtained in these
initial studies, much work is still required to elucidate the contri-
bution of these androgens to CRPC.8.3. Placenta
The placenta expresses CYP11A1 and catalyses StAR-
independent (Sugawara et al., 1995) de-novo steroidogenesis
probably facilitated by MLN64 with StAR-like activity (Bose et al.,
2000). De-novo steroidogenesis in the placenta yields mainly
PREG and PROG due to low levels of CYP17A1. However, CYP17A1
activity is sufﬁcient for the production of T, E1 and E2, as has been
demonstrated for trophoblasts (Escobar et al., 2011). In addition,
the placenta possesses the enzymatic machinery capable of con-
verting C19 steroids derived from the foetal adrenal and liver
(DHEAS and 16aOH-DHEA, respectively) to oestrogens during their
transplacental passage (Miller and Auchus, 2011). This mechanism
protects the mother (and female foetus) from virilisation by the
high concentrations of C19 steroid released into circulation by the
foetal adrenal (Conte et al., 1994). However, 5a-reduced androgens
cannot be aromatised and therefore can transfer from fetus to
mother unhindered by the placenta, which is observed e.g. in
aromatase deﬁciency and PORD. C19 steroid conversion in the
placenta thus has a protective systemic function rather than an
intracrine function.
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9.1. Skin
Several cellular components of the interfollicular epidermis and
pilosebaceous unit have the capability of de-novo steroid biosyn-
thesis supported by StAR activity (Anuka et al., 2013). The resulting
steroids include glucocorticoids and androgens and these pathways
were reviewed in (Labrie et al., 2000; Nikolakis et al., 2016;
Slominski et al., 2013). C19 steroids are produced from cutaneous
cholesterol via the classical D5 pathway. Circulating DHEA can also
be used as a precursor to produce active androgens by 3bHSD, 5a-
reductase and reductive 17bHSD activity (Nikolakis et al., 2016;
Slominski et al., 2013). In fact, studies with cultured sebocytes
suggest that circulating DHEAmay be themore important source of
androgen precursors (Chen et al., 2010). Local androgen availability
in the skin is necessary to stimulate sebum secretion and hair
growth. The generation of DHT is essential for beard growth
(Diamond et al., 1996; Messenger, 1993). Functional comparison of
different epidermal cell types hint at differential functions for
androgen biosynthesis and inactivation (Fritsch et al., 2001).
The presence of SRD5A1 allows for the local production of DHT
(Luu-The et al., 1994), with the 5a-dione pathway bypassing T being
the preferred route (Samson et al., 2010; Sugimoto et al., 1995)
(Fig. 6). Acne vulgaris and androgenic alopecia are associated with
local androgen hyperproduction. Acne-prone skin expresses higher
levels of androgen generating enzymes than non-acne-prone skin
(HSD17B3 and AKR1C3 converting A4 to T, STS and SRD5A1; sum-
marized in (Nikolakis et al., 2016)). Local over-production of DHT
has been proposed as cause of androgenic alopecia (Lee et al., 2015;
Sawaya and Price, 1997) and 5a-reductase inhibitors are an estab-
lished treatment for male pattern alopecia (Kaufman and Dawber,
1999).
In the skin, A4 and T can be aromatised to oestrogens, which
induce beneﬁcial effect on keratinocyte proliferation, production of
extracellular matrix components and wound healing (Kanda and
Watanabe, 2004a, 2004b; Raine-Fenning et al., 2003). Down-
stream metabolites of DHT are AST and 3a-adiol and the back
conversion of the 3a-reducedmetabolites is also possible. UGTs and
SULTs are expressed and may contribute to phase 2 metabolism
(Slominski et al., 2013). In addition, DHEA can be 7a-hydroxylated
by CYP7B1, which is expressed in the skin (Hennebert et al., 2007),
thereby preventing its metabolism to active androgens.
9.2. Salivary gland
Steroid measurements in saliva can be superior to that of serum
as they rely on a non-invasive, cheap collection technique and are
representative of the bioavailable, non-protein bound, levels of the
steroid that can passively diffuse from circulation into saliva in the
salivary glands (Vining et al., 1983). A range of liquid chromatog-
raphy tandem mass spectrometry assays for salivary cortisol/
cortisone and salivary androgens have thus been developed and
implemented in routine clinical laboratories (Keevil, 2016). It is
therefore essential that steroid metabolism in the salivary glands,
which often lead to altered concentrations in saliva compared to
serum concentrations, are understood in detail to correctly inter-
pret salivary steroid concentrations in their systemic context.
Salivary glands express STS, SULT2B1, HSD3B1, AKR1C3, SRD5A1 and
CYP19A1 and the activity of the encoded enzymes allows for the
conversion of circulating DHEAS and DHEA to DHT and oestrogens
(Spaan et al., 2009). Low local HSD3B1 expression coupled to
derangement of subcellular compartmentalization have been sug-
gested to lead to impaired 5a-reductase activity in Sjoergen's
syndrome resulting in local DHT deﬁciency and oestrogen excess, asreﬂected by salivary concentrations (Konttinen et al., 2015; Porola
et al., 2008; Spaan et al., 2009). However, in-vitro studies with
homogenised submandibular and parotid glands showed a prefer-
ence for oxidative 17bHSD activity (T/ A4 etc.) (Blom et al., 1993;
Djoseland et al., 1982). Oxidative HSD11B2 is present in the parotid
gland (Hirasawa et al., 1997; Smith et al., 1996) resulting in a
signiﬁcantly higher cortisone/cortisol ratio in saliva than in serum
(Hawley and Keevil, 2016) andmight thus also affect the ratio of 11-
keto to 11b-hydroxy androgens.
10. Kidney androgen metabolism and renal excretion of
androgens
10.1. The kidney as an androgen-metabolising organ
Surprisingly the kidney has been shown to be able to catalyse
the biosynthesis of active androgens using PREG as precursor for
DHEA production by CYP17A1 (Quinkler et al., 2003). DHEA could
be further metabolised to T, via A4 or 5a-dione, and the resulting T
could be 5a-reduced to DHT. Additionally, the expression of genes
(AKR1D1 and AKR1C2) encoding enzymes contributing to phase 1
metabolism and inactivation of androgens have been demonstrated
(Quinkler et al., 2003). It should, however, be noted that the tissue
used in this study was derived from tumour nephrectomies, thus
bringing into question the relevance of these results to the healthy
kidney. The kidney may be the major site of the generation of the T
17a-epimer “epitestosterone” (EpiT, 17a-hydroxytestosterone),
which has weak antiandrogenic functions and may inhibit certain
steroidogenic enzymes. EpiT circulates with low nM concentrations
and EpiT/T ratios are between 0.1 for women and up to 1 in men as
measured in serum of healthy subjects by immunoassay (Havlikova
et al., 2002). The ratio of urinary T and EpiT-glucuronide is used as
an indicator of exogenous T administration in doping analysis
(Mareck et al., 2010; Shackleton et al., 1997a, 1997b; Wada, 2015).
Given its high concentrations, the physiological effects of EpiT re-
quires further research. Furthermore, it is possible that current LC-
MS/MS assays used for the determination of serum T might erro-
neously include EpiT in their T measurements due to limited res-
olution. While there is no interconversion of T and EpiT excluding T
as the direct precursor to EpiT, a reductive 17aHSD (product of
AKR1C21) has been isolated from the mouse and has been shown to
convert 17-keto steroids to their 17a-hydroxyl, thus suggesting that
A4 could be the direct precursor to EpiT. This enzyme was specif-
ically expressed in the mouse kidney (Bellemare et al., 2005).
Excreted metabolites of EpiT are 5a- and 5b-androstane-3a,17a-
diols (Piper et al., 2009; Shackleton et al.,1997b;Wilson and Lipsett,
1966). Elimination of EpiT thus follows the same pathways as T.
The kidney has high levels of HSD11B2 activity which protects
the mineralocorticoid receptor from activation by cortisol by
inactivating it to cortisone (Edwards and Stewart, 1991; Funder
et al., 1988). The kidney is therefore also likely a site of the con-
version of 11-hydroxy C19 steroids to their corresponding 11-keto
forms. Signiﬁcantly, it is the 11-keto C19 steroids that are more
androgenic than their 11-hydroxy precursors (Storbeck et al., 2013)
and therefore while the kidney inactivates glucocorticoids it may
play a vital role in activating 11-oxygenated androgens. Indeed, a
recent study showed that while 11OHA4 and 11OHT are of adrenal
origin, differences in the concentration of the individual 11-
oxygenated steroids in the adrenal vein and inferior vena cava
suggest that 11KA4 and 11KT may instead be formed in peripheral
tissues (Turcu et al., 2016). The signiﬁcant levels of 11KA4measured
in the serum of healthy premenopausal woman (O'Reilly et al.,
2016) supports the involvement of peripheral tissue such as the
kidney, especially considering that the adrenal expresses only low
levels of HSD11B2 (Coulter et al., 1999).
Table 3
Urinary concentration of C19 steroid metabolites determined by gas chroma-
tography mass spectrometry after de-conjugation. All values are shown in mg/
24 h. The details of the original studies are given in the footnotes below the table.
Precursor metabolites Women Men
DHEA 111 (57e222)a
204 (82e378)c
396 (179e662)a
355 (151e880)c
16aOH-DHEA 278 (188e666)a
7bOH-DHEA 90 (70e100)b
5-androstenediol (5-diol) 78 (47e158)c 151 (94e234)c
Androgen metabolite
Androsterone (AST) 936 (733e1442)a
1047c
2072 (1600e3067)a
2138c
790 (760e830)b
Etiocholanolone (ETIO) 1321 (837e2041)a
955c
2066 (1539e2468)
1549c
920 (880e970)b
11bOH-AST* 407 (315e655)a 1014 (681e1416)a
380 (340e440)b
11bOH-ETIO* 236 (110e375)a 281 (198e498)a
190 (160e220)b
11-keto-AST* 160 (120e190)b
11-keto-ETIO* 319 (190e507)a 402 (317e644)a
*metabolite of both glucocorticoids and 11-oxygenated androgens to different ex-
tents (Shackleton et al., 2008).
a Arlt et al. (2011), median (interquartile range), 62 women and 26 men, age 18-
60.
b Kotlowska et al. (2017), median (interquartile range), combined values for 25
women and 12 men, age >40.
c Remer et al. (2005), mean (interquartile range), 25 girls and 25 boys, age 17e18.
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The main route of androgen excretion is the renal elimination of
the conjugated metabolites. Sulfo- and glucoconjugates are
excreted in different ratios for every androgen, while the excretion
of free forms is negligible (Buiarelli et al., 2004). Renal excretion of
conjugates takes advantage of (1) the hydrophilic water-soluble
nature of steroid conjugates and (2) the fact that their transport
across the cell membrane requires active transport mechanisms
which allow for the concentration of the molecules on one side of
the membrane (Pritchard and Miller, 1996; VanWert et al., 2010).
Organic anion transporters are highly expressed in renal epithelia
(Emami Riedmaier et al., 2012). Steroid sulfates are generally
excreted at a lower rate than their glucuronidated counterparts as
STS catalyse their desulfation. Besides the classical conjugates, T
metabolites conjugated with cysteine have been detected in urine
and plasma (Fabregat et al., 2013).
As urine collection is non-invasive it is a preferable matrix for
steroid analysis. In general, total levels of metabolites
(free þ conjugated) are measured after de-conjugation by b-
glucuronidase treatment. AST and ETIO are measured as repre-
sentatives of active androgens, while DHEA and 16aOH-DHEA are
measured as representatives of direct androgen precursors (Arlt
et al., 2011; Krone et al., 2010). Amounts of excreted androgen
and precursor metabolites from typical urinary steroid proﬁles
excreted in a 24 h-period are summarised in Table 3 (Arlt et al.,
2011; Kotlowska et al., 2017; Remer et al., 2005). Urinary 11-
oxygenated AST and 11-oxygenated ETIO originate from androgen
and glucocorticoid metabolism, however in different ratios. While
urinary 11-oxygenated ETIO is predominantly a product of gluco-
corticoid metabolism, urinary 11-oxygenated AST results mainly
from 11-oxygenated androgens (Jones et al., 2016; Shackleton et al.,
2008). As previously mentioned, 5b-reduction (/ ETIO) is indica-
tive of hepatic metabolism (Chen and Penning, 2014), while 5a-
reduction (/ AST) takes place in most peripheral tissues (Russell
and Wilson, 1994). In the context of intracrinology, 5a-reduced
metabolites are thus of particular interest. The urinary steroid
metabolome represents the total of all steroid biosynthetic and
metabolising pathways and has proven to be a speciﬁc and sensi-
tive biomarker for the diagnosis of steroidogenic disease (Arlt et al.,
2011). De-conjugation by b-glucuronidase is time-consuming and
may lead to imprecision due to variability in hydrolysis efﬁciency
(Trabert et al., 2016), but to date only a limited number of methods
for the simultaneous measurement of free, sulfated and glucur-
onidated androgens have been established, although signiﬁcant
progress has been made (Badoud et al., 2011; Doue et al., 2015;
Galuska et al., 2013). Such approaches also allow the investigation
of dysfunction of conjugation pathways in a single run.
As intracrine androgen activation takes place in the cell andmay
start with the uptake of an androgen precursor and end with the
efﬂux of an inactive androgen metabolite, circulating levels of
active androgens are not a valid reﬂection of total body androgen
action (O'Reilly et al., 2014b). The assessment of circulating pre-
cursors in particular A4 (Keevil, 2014; O'Reilly et al., 2014b; Pasquali
et al., 2016) including 11-oxygenated C19 steroids (O'Reilly et al.,
2016) or androgen metabolites AST-glucuronide, 3a-adiol-3-
glucuronide and 3a-adiol-17-glucuronide (Labrie et al., 1997a,
1997b; Vandenput et al., 2007) are thus recommended to assess
androgen burden.
11. Conclusions
Besides its essential function for normal male sexual develop-
ment (Auchus and Miller, 2012; Krone et al., 2007), androgen
intracrinology plays a crucial role for physiology of peripheraltissues in both sexes. Its dysregulation can impair local and sys-
temic metabolic homeostasis and promote sex hormone-
dependent cancer, but precise mechanisms remain to be eluci-
dated. Model systems must be carefully chosen and signiﬁcant
differences in adrenal development, C19 steroidogenesis and sub-
sequent metabolism between humans and common animal
models, i.e. rodent and non-human primates, must be taken into
account. Because of the major contributions of intracrinology to the
androgen levels a peripheral target cell is exposed to, the mea-
surement of androgen precursors (O'Reilly et al., 2014b; Pasquali
et al., 2016) and metabolites (Labrie et al., 2006; Vandenput et al.,
2007) is recommended to assess local androgen burden and asso-
ciated health risks. Therefore, more efforts are required to exploit
the progress in steroid chromatography/mass spectrometry for
comprehensive C19 steroid proﬁling and to systematically evaluate
such proﬁles for the establishment of validated links to speciﬁc
clinical conditions. The tissue-speciﬁcity of intracrine pathways in
combination with the differential expression of hydroxysteroid
dehydrogenases and SRD5A isoforms renders the inhibition of
intracrine pathways a promising treatment option in addition to or
as a replacement of androgen receptor blockade therapies in sex
steroid-dependent cancer. The proof-of-concept has been estab-
lished by aromatase inhibition in breast cancer and 5a-reductase
inhibition in prostate hyperplasia (Chumsri et al., 2011; Lowe et al.,
2003; McConnell et al., 1998). Additionally, androgen biosynthesis
from C21 precursors can be reduced by CYP17A1 inhibition with
abiraterone as successfully applied for the treatment of CRPC
(Attard et al., 2008; de Bono et al., 2011; James et al., 2017). While
androgenmetabolism in reproductive tissues is well studied, less is
known to date about androgen action in non-classical target tis-
sues, such as the liver and skeletal muscle, which are major com-
partments responsible for metabolic regulation and metabolic
health. Emerging evidence suggests a signiﬁcant role of androgens
in metabolic dysfunction and metabolic disease. Furthermore, the
recent discovery of intracrine pathways for the metabolism of 11-
oxygenated C19 steroids requires further investigation at both the
L. Schiffer et al. / Molecular and Cellular Endocrinology 465 (2018) 4e2620systemic and intracrine levels, especially considering the additional
complexity associated with the regulation of these steroids by
HSD11B enzymes. Also, the reverse co-regulation of androgen and
glucocorticoid action (SRD5A enzymes and HSD11B2 activate an-
drogens, but inactivate glucocorticoids) is a striking phenomenon,
which must be unravelled taking tissue-speciﬁc conditions into
account, as both classes of hormones play key roles in metabolic
regulation.
While intracrinology has come a long way since its discovery,
much work is still required to understand the cell- and tissue-
speciﬁc intricacies of its physiological function in both health and
disease.
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